Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Antibody Response Before and After the Booster Dose of Inactivated Corona Vaccine in Antibody Deficient Patients Publisher



Movahedi M1 ; Movahedi M1 ; Parvaneh N1 ; Abolhassani H2, 3 ; Mahdavi M1 ; Mousavi Khorshidi MS1 ; Alizadeh F1 ; Shokri M4 ; Kalantari A5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Division of Allergy and Clinical Immunology, Pediatrics Center of Excellence, Children’s Medical Center Hospital, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Research Center for Primary Immunodeficiencies, Pediatrics Center of Excellence, Children’s Medical Center Hospital, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Division of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden
  4. 4. Department of Pediatrics, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran
  5. 5. Department of Immunology and Allergy, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

Source: Iranian Journal of Allergy# Asthma and Immunology Published:2024


Abstract

Patients with inborn errors of immunity (IEI) are among the high-risk groups regarding COVID-19. Receiving booster doses (third and fourth) in addition to the standard doses is recommended in these patients. This study investigated the antibody response before and after a booster dose of Sinopharm vaccine in IEI patients. Thirty patients (>12 years) with antibody deficiencies, referred to Imam Khomeini Hospital and Children's Medical Center in Tehran, were enrolled in this prospective cross-sectional study. All patients were fully vaccinated with the BBIBP-CorV vaccine (2 doses of Sinopharm). Initial measurements of anti-receptor-binding domain (anti-RBD) and anti-nucleocapsid (anti-N) IgG antibody responses were conducted by enzyme-linked immunosorbent assay (ELISA). Subsequently, all patients received a booster dose of the vaccine. Four to six weeks after booster injection, the levels of antibodies were re-evaluated. Twenty patients with common variable immunodeficiency (CVID), 7 cases with agammaglobulinemia and 3 patients with hyper IgM syndrome were studied. Anti-RBD IgG and anti-N IgG antibodies increased in all patients after the booster. Our results indicated the need of receiving booster doses of the COVID-19 vaccine in patients with antibody deficiencies, even for enhancing humoral immune response specially in patients with CVID. © 2024 Tehran University of Medical Sciences. All rights reserved.
Related Docs
View other Related Docs
1. Covid-19 Infection in Inborn Errors of Immunity and Their Phenocopies: A Systematic Review and Meta-Analysis, Infectious Diseases (2025)
2. Human Genetic and Immunological Determinants of Critical Covid-19 Pneumonia, Nature (2022)
3. Sars-Cov-2: Current Trends in Emerging Variants, Pathogenesis, Immune Responses, Potential Therapeutic, and Vaccine Development Strategies, International Immunopharmacology (2021)
4. New Presentation of Cd27 Deficiency; Coronary Ectasia and Covid-19, Iranian Journal of Allergy# Asthma and Immunology (2023)
5. Genetic and Immunologic Evaluation of Children With Inborn Errors of Immunity and Severe or Critical Covid-19, Journal of Allergy and Clinical Immunology (2022)
6. Vlp-Based Covid-19 Vaccines: An Adaptable Technology Against the Threat of New Variants, Vaccines (2021)
7. Appraisal of Sars-Cov-2 Mutations and Their Impact on Vaccination Efficacy: An Overview, Journal of Diabetes and Metabolic Disorders (2022)
8. The Clinical Impact of Mrna Therapeutics in the Treatment of Cancers, Infections, Genetic Disorders, and Autoimmune Diseases, Heliyon (2024)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (17)
Alireza Shafiei Esfidvajani (1)
Other Related Docs
9. Molecular Variants of Sars-Cov-2: Antigenic Properties and Current Vaccine Efficacy, Medical Microbiology and Immunology (2022)
10. Establishment of National Primary Immunodeficiency Network, Requisite of Health Organization and Final Stage of Polio Eradication: Review Article, Tehran University Medical Journal (2020)
11. How Do Nuclear Factor Kappa B (Nf-Κb)1 and Nf-Κb2 Defects Lead to the Incidence of Clinical and Immunological Manifestations of Inborn Errors of Immunity?, Expert Review of Clinical Immunology (2023)
12. Nanostructures for Prevention, Diagnosis, and Treatment of Viral Respiratory Infections: From Influenza Virus to Sars-Cov-2 Variants, Journal of Nanobiotechnology (2023)
13. Short-Term Sars-Cov-2 Re-Infection Rate in Vaccinated Health Workers Based on Received Vaccines: A Cross-Sectional Study, Current Respiratory Medicine Reviews (2023)
14. Efficacy and Safety of a Protein-Based Sars-Cov-2 Vaccine: A Randomized Clinical Trial, JAMA Network Open (2023)
15. Impact of Sars-Cov-2 Pandemic on Patients With Primary Immunodeficiency, Journal of Clinical Immunology (2021)
16. Characterization of Stability, Safety and Immunogenicity of the Mrna Lipid Nanoparticle Vaccine Iribovax® Against Covid-19 in Nonhuman Primates, Journal of Controlled Release (2023)
17. Covid-19: Review of a 21St Century Pandemic From Etiology to Neuro-Psychiatric Implications, Journal of Alzheimer's Disease (2020)
18. A Systematic Review and Meta-Analysis of Immune Response Against First and Second Doses of Sars-Cov-2 Vaccines in Adult Patients With Hematological Malignancies, International Immunopharmacology (2022)
19. Recent Developments in Sars-Cov-2 Vaccines: A Systematic Review of the Current Studies, Reviews in Medical Virology (2023)
20. The Middle East and North Africa Diagnosis and Management Guidelines for Inborn Errors of Immunity, Journal of Allergy and Clinical Immunology: In Practice (2023)
21. Delving Into Revolutionary Sars-Cov-2 Vaccine Approaches: Molecular and Virological Examinations; Principles of Sars-Cov-2 Vaccine Platform; [Adentrandose En Enfoques Revolucionarios De Vacunas Sars-Cov-2: Examenes Moleculares Y Virologicos; Principios De La Plataforma De Vacunas Sars-Cov-2], Vacunas (2024)
22. Cellular Mechanisms and Clinical Applications for Phenocopies of Inborn Errors of Immunity: Infectious Susceptibility Due to Cytokine Autoantibodies, Expert Review of Clinical Immunology (2023)
23. Common Presentations and Diagnostic Approaches, Stiehm's Immune Deficiencies: Inborn Errors of Immunity (2020)
24. Sars-Cov-2 Antibody Response After Bbibp-Corv (Sinopharm) Vaccination in Cancer Patients: A Case-Control Study, Frontiers in Medicine (2023)
25. The Autoimmune Manifestations in Patients With Genetic Defects in the B Cell Development and Differentiation Stages, Journal of Clinical Immunology (2023)
26. X-Linked Tlr7 Deficiency Underlies Critical Covid-19 Pneumonia in a Male Patient With Ataxia-Telangiectasia, Journal of Clinical Immunology (2022)
27. The Effectiveness of Covid-19 Vaccines in Reducing the Incidence, Hospitalization, and Mortality From Covid-19: A Systematic Review and Meta-Analysis, Frontiers in Public Health (2022)
28. The Role of Type I Interferon in the Treatment of Covid-19, Journal of Medical Virology (2022)
29. Point-Of-Use Rapid Detection of Sars-Cov-2: Nanotechnology-Enabled Solutions for the Covid-19 Pandemic, International Journal of Molecular Sciences (2020)
30. Immunologic Response, Efficacy, and Safety of Vaccines Against Covid-19 Infection in Healthy and Immunosuppressed Children and Adolescents Aged 2 – 21 Years Old: A Systematic Review and Meta-Analysis, Journal of Clinical Virology (2022)
31. Autoimmunity in Monogenic Combined Immune Deficiencies With Associated or Syndromic Features, Frontiers in Immunology (2022)
32. Effectiveness of Covid-19 Vaccines Against Delta (B.1.617.2) Variant: A Systematic Review and Meta-Analysis of Clinical Studies, Vaccines (2022)
33. General Considerations, Pulmonary Manifestations of Primary Immunodeficiency Diseases (2018)
34. The Effect of Covid-19 Mrna Vaccines Against Postvaccination Laboratory-Confirmed Sars-Cov-2 Infection, Symptomatic Covid-19 Infection, Hospitalization, and Mortality Rate: A Systematic Review and Meta-Analysis, Expert Review of Vaccines (2022)
35. Nf-Κb Pathway Variants in Iranian Patients With Inborn Errors of Immunity, Expert Review of Clinical Immunology (2025)
36. Breakthrough Sars-Cov-2 Infections After Vaccination: A Critical Review, Human Vaccines and Immunotherapeutics (2022)
37. Clinical Heterogeneity in Families With Multiple Cases of Inborn Errors of Immunity, Clinical Immunology (2024)
38. Autoimmune Versus Non-Autoimmune Cutaneous Features in Monogenic Patients With Inborn Errors of Immunity, Biology (2023)
39. Overview of the Current Promising Approaches for the Development of an Effective Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) Vaccine, International Immunopharmacology (2020)
40. Decreased Expression of Hsa-Mir-142-3P and Hsa-Mir-155-5P in Common Variable Immunodeficiency and Involvement of Their Target Genes and Biological Pathways, Allergologia et Immunopathologia (2025)
41. Recent Advances in Passive Immunotherapies for Covid-19: The Evidence-Based Approaches and Clinical Trials, International Immunopharmacology (2022)